No Data
GTJA: The Global competitiveness of domestic Innovative Drugs is becoming prominent, and the Operation turning point is approaching.
The current trend in the Innovative Drugs Industry is positive, with continuous marginal improvements. The negotiation time for medical insurance will be advanced in 2025, and the category C directory is expected to be released within the year. It is anticipated that the price drop for biosimilars in the centralized procurement will be moderate. Attention should be paid to recent academic conferences, and there is a bullish outlook on leading Innovative Drug companies.
Trending Industry Today: CARSGEN-B Leads Gains In Pharmaceutical Companies Stocks
Zhaoyun International: The Pharmaceutical price policy is expected to be optimized, and FSG Medical Serv A is accelerating commercialization.
Zhao Yin International's valuation repair in the Pharmaceutical Industry.
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy
SKB BIO-B (06990.HK) established a market management service agreement with Kelong Jialin.
SKB BIO-B (06990.HK) announced that on February 12, 2025, the company entered into a market management service framework agreement with Corun Jiaxun, under which Corun Jiaxun and/or its affiliates will provide market management services to the company for the research and development of the recombinant epidermal growth factor receptor (EGFR) human-mouse chimeric monoclonal antibody (monoclonal antibody) Cetuximab N01 injection (formerly A140) (Datalay).
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
